person · Reporting owner
Seltzer Stacey Denenberg
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aimmune Therapeutics, Inc.
Report date October 10, 2020 · Filed October 14, 2020
Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-10 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-10-10 · Other · Disposed 10,221 · Balance 0 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-10-13 · Disposition to issuer · Disposed 7,840 · Balance 0 F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.29 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-13 · Disposition to issuer · Disposed 52,421 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.40 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-13 · Disposition to issuer · Disposed 19,755 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-13 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.79 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-13 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.90 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-13 · Disposition to issuer · Disposed 11,432 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.11 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-13 · Disposition to issuer · Disposed 15,398 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").
F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2023 Filed Jun 8, 2023 22:06 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001209191-23-035560 · doc4.xml · derivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:00 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-22-034171 · doc4.xml · derivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 19:14 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026338 · doc4.xml · derivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-04-07 F1 · derivative.exercise_date: The shares subject to the option vest on April 8, 2022. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 15,398 | $17.39 Strike: $17.11 | $267,771.22 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · derivative · entry 8 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,398 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 11,432 | $14.60 Strike: $19.90 | $166,907.20 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · derivative · entry 7 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,432 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 7,500 | $1.71 Strike: $32.79 | $12,825.00 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · derivative · entry 6 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 17,500 | $16.24 Strike: $18.26 | $284,200.00 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · derivative · entry 5 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 19,755 | $19.10 Strike: $15.40 | $377,320.50 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · derivative · entry 4 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,755 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 52,421 | $28.21 Strike: $6.29 | $1,478,796.41 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · derivative · entry 3 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,421 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerCommon Stock, $0.0001 par value | 7,840 | $34.50 | $270,480.00 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · nonDerivative · entry 2 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F2 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. Read SEC document |
| October 10, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | OtherCommon Stock, $0.0001 par value | 10,221 | $34.50 | $352,624.50 |
DisclosureSEC source: 0000899243-20-028177 · doc4.xml · nonDerivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:12 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 15,398 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0000899243-20-014609 · doc4.xml · derivative · entry 2 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,398 Underlying: Common Stock · 15,398 shares Expires 2030-05-26 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:12 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 7,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014609 · doc4.xml · nonDerivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,061 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 23, 2019 Filed May 28, 2019 21:19 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 11,432 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0000899243-19-014965 · doc4.xml · derivative · entry 2 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,432 Underlying: Common Stock · 11,432 shares Expires 2029-05-23 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 23, 2019 Filed May 28, 2019 21:19 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 6,442 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014965 · doc4.xml · nonDerivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,221 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 23, 2018 Filed May 24, 2018 17:09 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $32.79 | $0.00 |
DisclosureSEC source: 0000899243-18-013931 · doc4.xml · derivative · entry 2 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-23 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 23, 2018 Filed May 24, 2018 17:09 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-013931 · doc4.xml · nonDerivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 16:31 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | OtherCommon Stock | 29 | $0.00 | $0.00 |
DisclosureSEC source: 0000950142-17-002181 · es1701213_4-seltzer.xml · nonDerivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29 F1 · kind: On December 6, 2017, Aisling Capital III, LP and certain of its affiliated funds distributed a portion of the shares of common stock of the Issuer (the "Common Stock") beneficially owned by such funds to their partners for no consideration. In connection with the distributions, the reporting person received 29 shares of Common Stock. In accordance with Rule 16a-9, such acquisition is exempt from Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:06 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0000899243-17-014692 · doc4.xml · derivative · entry 1 Seltzer Stacey Denenberg · CIK 0001648895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2027-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.